Regulatory Affairs & Dossier Development Company in Australia | KMS Pharma
Strategic Regulatory Affairs & Global Dossier Solutions

Regulatory Affairs & Dossier Development Company in Australia

KMS Pharma operates as a dedicated Regulatory Affairs & Dossier Development Company in Australia, helping pharmaceutical sponsors navigate Therapeutic Goods Administration (TGA) approvals and global market access. We handle complete regulatory dossier preparation in Australia—covering ARTG listings and registrations, CTD/eCTD publishing, overseas GMP clearances, and cross-border submissions for the US, UK, and European markets.

Getting a medicine onto the Australian Register of Therapeutic Goods (ARTG) requires more than translating an overseas dossier into an Australian cover sheet. The Therapeutic Goods Administration (TGA) enforces strict local rules around Australian Reference Products, PIC/S GMP clearance for overseas manufacturing sites, and region-specific Module 1 formatting. As a seasoned Regulatory Affairs & Dossier Development Company in Australia, KMS Pharma supports local sponsors, generic developers, and international licence holders from early dossier planning through commercial approval.

Our regulatory and scientific writers work directly alongside your analytical and formulation teams. By catching Chemistry, Manufacturing, and Controls (CMC) gaps and biopharmaceutic discrepancies before lodgement, we help sponsors avoid screening rejections, shorten TGA Milestone clock-stops, and expand smoothly across ANZ, North America, and Europe.

01 / TECHNICAL EXCELLENCE

Expert Regulatory Dossier Preparation in Australia

Strong regulatory dossier preparation in Australia starts with aligning raw R&D stability data, method validations, and manufacturing batch records with TGA guidelines and ICH standards. Even minor inconsistencies between Module 2 summaries and Module 3 technical reports can trigger screening hurdles or multi-round Section 31 requests.

At KMS Pharma, we audit your source technical package before assembling a single folder. Our team converts complex laboratory findings into a clear, logically cross-referenced submission narrative—proactively justifying dissolution profiles, impurity limits, and container-closure compatibility so TGA evaluators get straightforward answers on first review.

01 / GAP AUDIT

Source Data Readiness Review

Examine batch analyses, analytical validation reports, and stability data to uncover compliance gaps ahead of TGA pre-submission planning.

02 / TECHNICAL AUTHORING

Module Compilation & Writing

Write clear Quality Overall Summaries (QOS), biopharmaceutic justifications, and Module 3 CMC files tailored to Australian evaluation criteria.

03 / POST-APPROVAL

ARTG Lifecycle Variations

Manage Category 3 and Category 1 variations, manufacturing site transfers, shelf-life extensions, and annual charge compliance.

A well-built regulatory dossier does more than tick compliance boxes—it prevents costly evaluation clock-stops and protects your commercial launch window.

02 / AUSTRALIAN MARKET ACCESS

TGA Registration for Generic Medicines in Australia

Securing TGA registration generics in Australia requires precise alignment with the Therapeutic Goods Act 1989 and Australian Regulatory Guidelines for Prescription Medicines (ARGPM). Generic sponsors must demonstrate bioequivalence against an approved Australian Reference Product—or provide a scientifically watertight biowaiver justification—while ensuring every overseas API and finished-product site holds valid TGA GMP clearance.

KMS Pharma manages the complete Category 1 prescription generic workflow, including pre-submission planning forms (PPF), comparable overseas regulator (COR) pathways, Product Information (PI) and Consumer Medicine Information (CMI) drafting, and TGO 91/92 compliant packaging artwork reviews.

01

Pre-Submission Planning & GMP Verification

Confirm the Australian Reference Product, determine standard vs. COR-A/COR-B evaluation pathways, and initiate TGA GMP clearance applications for manufacturing sites.

02

Australian Module 1 & PI/CMI Authoring

Compile bespoke Australian administrative forms, biopharmaceutic study summaries, Risk Management Plans (RMPs), and TGA-formatted PI and CMI drafts.

03

eCTD Lodgement & Milestone Tracking

Transmit validated sequences via the TGA Business Services (TBS) portal and manage evaluation milestones from Milestone 1 screening through ARTG entry.

03 / HARMONISED STRUCTURING

CTD Dossier Preparation in Australia

While Australia follows the international Common Technical Document (CTD) architecture, local evaluators scrutinise specific regional nuances—especially within Module 1 and biopharmaceutic summaries. Thorough CTD dossier preparation in Australia ensures that every claim in Module 2 maps cleanly back to raw batch execution records and analytical data in Modules 3, 4, and 5.

Our regulatory specialists structure cohesive CTD packages that satisfy TGA evaluators without requiring wholesale rewrites when you expand into New Zealand (Medsafe) or other PIC/S member territories.

✓

Module 1 Australian Regional Files: Prepare application forms, GMP clearance evidence, patent certifications, PI/CMI documents, and TGO-compliant label mock-ups.

✓

Module 2 Summaries & Overviews: Author concise Quality Overall Summaries (QOS), Biopharmaceutic Summaries, and Clinical Overviews backed by tabulated data.

✓

Module 3 Quality (CMC): Consolidate drug substance (API) synthetic controls, excipient specifications, formulation development, process validation, and stability data.

✓

Modules 4 & 5 Non-Clinical & Clinical: Organize literature-based justifications, toxicological impurity assessments, and bioequivalence study reports with statistical audits.

04 / DIGITAL SUBMISSION MANAGEMENT

eCTD Dossier in Australia Publishing & Lifecycle Management

Electronic Common Technical Document (eCTD) formatting is mandatory for prescription medicine submissions to the TGA. Compiling an error-free eCTD dossier in Australia requires strict compliance with the Australian eCTD Regional Specification (au-regional.xml), accurate envelope metadata, and clean PDF navigation.

KMS Pharma uses validated eCTD publishing tools to build, verify, and package sequences that pass TGA technical validation on the first attempt—from initial sequence (0000) through Section 31 responses, post-approval variations, and periodic safety updates.

TECH 01 / AU-XML

Regional XML Backbone

Build and validate Australian regional XML envelopes, sequence numbers, and submission-type attributes against current TGA validation rules.

TECH 02 / NAVIGATION

Hyperlinking & Bookmarks

Verify internal bookmarks, cross-module hyperlinks, OCR text legibility, and font embedding so evaluators can review dense files effortlessly.

TECH 03 / LIFECYCLE

Sequence Version Control

Maintain accurate document lifecycle operators (New, Replace, Delete, Append) across multi-year ARTG product histories.

05 / QUALITY & TECHNICAL EXCELLENCE

CMC Regulatory Consultant in Australia

Chemistry, Manufacturing, and Controls (CMC) queries account for the majority of TGA evaluation delays. Working with an experienced CMC regulatory consultant in Australia helps sponsors present airtight scientific justifications for API synthesis, polymorphism, dissolution discrimination, and shelf-life assignments.

Our CMC specialists collaborate directly with your formulation scientists and contract manufacturers. We review restricted and open parts of Drug Master Files (DMFs), verify nitrosamine and elemental impurity risk assessments (ICH M7 / Q3D), and ensure batch data supports commercial specifications.

CMC / SUBSTANCE

Drug Substance (3.2.S)

Audit synthetic routes, starting material justifications, critical process parameters, genotoxic impurity controls, and DMF Letters of Access.

CMC / PRODUCT

Drug Product (3.2.P)

Compile pharmaceutical development reports, Quality by Design (QbD) control strategies, commercial scale-up validation, and container closure data.

CMC / ANALYTICAL

Method Validation & Stability

Verify stability-indicating assay validations under ICH Q2 and establish defensible Australian shelf-life and storage conditions under ICH Q1A/Q1E.

06 / NORTH AMERICAN ACCESS

ANDA Filing Support in Australia for US Market Entry

Australian pharmaceutical developers and license holders looking to commercialise generics in the United States must navigate Abbreviated New Drug Application (ANDA) rules under 21 CFR 314.94 and GDUFA II/III commitments. Simply repurposing an Australian TGA dossier will trigger an immediate US FDA Refuse-to-Receive (RTR) notice.

KMS Pharma delivers specialized ANDA filing support in Australia, bridging Australian and international R&D datasets with strict US FDA expectations. We align dissolution testing with FDA Office of Generic Drugs (OGD) databases, structure Question-based Review (QbR) Quality Overall Summaries, and prepare eCTD packages for Electronic Submissions Gateway (ESG) lodgement.

✓

US Reference Listed Drug (RLD) Alignment: Guide Q1/Q2 sameness assessments, reverse engineering, and bioequivalence protocols matched to the US Orange Book RLD.

✓

Pre-Assigned Numbers & DMF Coordination: Manage FDA FEI facility registrations, pre-assigned ANDA numbers, and active API/packaging DMF Letters of Access.

✓

Controlled Correspondence & RTR Prevention: Draft FDA Controlled Correspondence for complex generics and run comprehensive Refuse-to-Receive checklists prior to filing.

07 / UNITED KINGDOM ACCESS

MHRA Marketing Authorisation in Australia Programmes

Because Australia's TGA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) share deep regulatory alignment—including the Access Consortium work-sharing initiative and the UK International Recognition Procedure (IRP)—many Australian sponsors pursue parallel UK registrations.

KMS Pharma manages MHRA marketing authorisation in Australia expansion strategies, adapting existing TGA dossiers for UK national submissions or IRP pathways. We handle UK-specific Module 1 administration, Windsor Framework territory requirements, Summary of Product Characteristics (SmPC) formatting, and Patient Information Leaflet (PIL) user testing.

✓

IRP & Access Consortium Routing: Leverage TGA approval reports to accelerate MHRA review under the International Recognition Procedure or joint Access filings.

✓

UK-Specific Module 1 Conversion: Adapt Australian PI/CMI texts into compliant UK SmPC/PIL formats alongside UK QPPV and pharmacovigilance system summaries.

✓

UK Portal Submission Management: Publish UK-valid eCTD sequences and coordinate MHRA assessment responses through to marketing authorisation grant.

08 / EUROPEAN EXPANSION

EU Dossier for Generic Medicines in Australia Strategies

Expanding an Australian generic portfolio into the European Economic Area requires adapting dossiers to meet European Medicines Agency (EMA) and national Competent Authority rules. Coordinating an EU dossier generic in Australia workflow involves bridging bioequivalence studies to an approved European Reference Medicinal Product (EU RMP) and structuring multi-country submissions.

KMS Pharma converts Australian CTD master files into compliant European dossiers for Decentralised Procedures (DCP), Mutual Recognition Procedures (MRP), and National submissions—managing Reference Member State (RMS) slot bookings, environmental risk assessments (ERA), and European readability testing.

01 / EU RMP BRIDGING

Reference Product Strategy

Evaluate EU reference medicinal product equivalence, biowaiver eligibility, and comparative dissolution profiles against European standards.

02 / DCP & MRP ROUTING

Member State Coordination

Support Reference Member State (RMS) selection, Concerned Member State (CMS) validation, and harmonised QRD template product information.

03 / DUAL-TRACK FILES

TGA-to-EU Dossier Conversion

Re-format Module 1 regional files, QP declarations, and EU eCTD envelopes so single core datasets serve both Australia and Europe.

09 / OBJECTION REMEDIATION

Rapid Deficiency Response Support in Australia

Receiving a Section 31 Request for Information from the TGA—or a Complete Response Letter (CRL) from the FDA or MHRA—puts commercial launch dates at risk. Resolving evaluator objections takes more than rephrasing existing text; it requires clear root-cause science, targeted supplementary data, and concise answers that directly resolve the assessor's concern.

KMS Pharma provides hands-on deficiency response support in Australia. We dissect every quality, biopharmaceutic, and clinical question, coordinate rapid laboratory or statistical justifications with your technical teams, and publish complete response sequences well ahead of clock-stop deadlines.

01

Question Triage & Root-Cause Strategy

Break down TGA Section 31 or overseas agency queries to separate administrative clarifications from questions requiring new analytical or batch data.

02

Supporting Data & Technical Justification

Work with QC labs and manufacturing sites to generate dissolution profiles, impurity fate-and-purge arguments, or updated validation summaries.

03

Response Authoring & eCTD Sequence Filing

Draft clear point-by-point response documents, update affected Module 1–3 files, and submit a validated eCTD response sequence on schedule.

10 / COMMERCIAL ALLIANCES

Dossier Licensing & Out-Licensing in Australia

Commercialising pharmaceutical assets across Australia, New Zealand, and international territories often relies on strategic partnerships. Structuring dossier licensing out-licensing in Australia deals allows R&D developers to monetise validated dossiers while enabling local distributors and marketing authorisation holders to expand their product lines without multi-year development costs.

KMS Pharma supports both licensors and licensees with technical due diligence, ARTG sponsorship transfer planning, GMP clearance verification, and gap assessments to determine what local bridging work is needed before commercial launch.

✓

Pre-Deal Regulatory Due Diligence: Audit target dossiers for data integrity, DMF availability, bioequivalence validity, and TGA compliance gaps before signing term sheets.

✓

Territory Adaptation Roadmaps: Map out exact timelines and costs needed to convert an EU, UK, or US dossier into an ARTG-ready Australian submission.

✓

ARTG Sponsorship & Licence Transfers: Manage change-of-sponsorship notifications, variation filings, and updated packaging artwork transitions smoothly.

11 / FAST-TRACK PORTFOLIO

Ready Dossiers for Licensing in Australia

For pharmaceutical marketers and distributors seeking immediate portfolio growth, acquiring ready dossiers for licensing in Australia eliminates early formulation and bioequivalence risks. However, a "ready" dossier only delivers commercial value if its underlying CMC data, analytical methods, and manufacturing site GMP credentials hold up under TGA scrutiny.

KMS Pharma connects Australian and regional commercial partners with audit-verified, submission-ready generic and specialty dossiers across high-demand therapeutic categories—backed by ongoing cGMP supply support and complete eCTD packages.

PORTFOLIO / ORAL

Solid Oral Dosages

Immediate-release and modified-release tablets and capsules spanning cardiovascular, central nervous system, anti-infective, and metabolic therapies.

PORTFOLIO / STERILE

Injectables & Parenterals

Small-volume liquid vials, lyophilized injectables, and ophthalmic solutions backed by validated aseptic processing and container-closure data.

PORTFOLIO / SPECIALTY

Topicals & Oral Liquids

Creams, gels, ointments, and oral suspensions supported by rheological profiling, preservative efficacy data, and comparative quality testing.

Accelerate Your Australian & Global Regulatory Milestones

Whether preparing a TGA Category 1 registration, publishing an Australian eCTD sequence, resolving complex CMC deficiencies, or sourcing ready dossiers for licensing, KMS Pharma brings practical regulatory and scientific expertise to every stage of your submission.

Schedule a Regulatory Consultation
Regulatory requirements, submission criteria, and evaluation timelines vary based on molecule classification, dosage form, legal basis of submission, and jurisdictional directives. Details provided herein represent professional regulatory capabilities and do not constitute an explicit regulatory guarantee of approval. Confirm project-specific scopes and health authority guidelines with KMS Pharma.